Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Their CryptoMap platform leverages immunopeptidomics, genomics, and a bioinformatics pipeline, allowing the identification of ...

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...